Clinical use of antidepressant therapy and associated cardiovascular risk

Drug, Healthcare and Patient Safety

Volumn 4, Issue 1, 2012, Pages 93-101

  Stephen Waring, W ^a  

^a YORK TEACHING HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Arrhythmia; Electrocardiography; QT prolongation; Selective serotonin reuptake inhibitors; Torsades de pointes; Tricyclic antidepressants

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE ASSOCIATION; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; GRAND MAL SEIZURE; HEART ARRHYTHMIA; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; HYPOTENSION; MYOCARDITIS; QT INTERVAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUDDEN DEATH; TACHYCARDIA; TORSADE DES POINTES;

EID: 84866174353     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S28804     Document Type: Review

References (91)

1. Medicines and Healthcare products Regulatory Authority. Citalopram and escitalopram: QT interval prolongation: New maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Available from: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON137769. Accessed July 27, 2012.
2. Food and Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm. Accessed July 27, 2012.
3. Howland RH. A critical evaluation of the cardiac toxicity of citalopram: part 2. J Psychosoc Nurs Ment Health Serv. 2011;49:13-16.
4. Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf. 2011;20:903-913.
5. Gintant G. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther. 2011;129:109-119.
6. Shimizu W, Horie M. Phenotypic manifestations of mutations in genes encoding subunits of cardiac potassium channels. Circ Res. 2011;109: 97-109.
7. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. Scientific World Journal. 2012; 2012:212178.
8. Sauer AJ, Newton-Cheh C. Clinical and genetic determinants of torsade de pointes risk. Circulation. 2012;125:1684-1694.
9. Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006;43:1603-1611.
10. Chung AK, Chua SE. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol. 2011;25: 646-666.
11. Thomas SH, Drici MD, Hall GC, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand. 2010;122: 345-355.
12. Malik M, Hnatkova K, Sisakova M, Schmidt G. Subject-specific heart rate dependency of electrocardiographic QT, PQ, and QRS intervals. J Electrocardiol. 2008;41:491-497.
13. Chan A, Isbister GK, Kirkpatrick CM, Dufful SB. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM. 2007;100:609-615.
14. Waring WS, Graham A, Gray J, Wilson AD, Howell C, Bateman DN. Evaluation of a QT nomogram for risk assessment after antidepressant overdose. Br J Clin Pharmacol. 2010;70:881-885.
15. Extramiana F, Maison-Blanche P, Cabanis MJ, Ortemann-Renon C, Beaufils P, Leenhardt A. Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther. 2005;77:247-258.
16. Luo S, Michler K, Johnston P, MacFarlane PW. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol. 2004;37 Suppl:81-90.
17. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007;22:39-43.
18. Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? Cardiology. 2000;94:99-102.
19. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: a familial cause of sudden death. Circulation. 2003;108:965-970.
20. Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation. 2004;109: 30-35.
21. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome SQT3 is caused by a mutation in the KCNJ2 gene. Circ Res. 2005;96: 800-807.
22. Committee for Proprietary Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by noncardiovascular medicinal products (CPMP/986/96) London, UK: EMEA; 1997. Available from: http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs%5Ccpmp.pdf. Accessed July 27, 2012.
23. Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electrocardiol. 2007;40:228-234.
24. Labad J, Price JF, Strachan MW, et al. Symptoms of depression but not anxiety are associated with central obesity and cardiovascular disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetologia. 2010;53:467-471.
25. McIntyre RS, Park KY, Law CW, et al. The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs. 2010;24:741-753.
26. López-León S, Aulchenko YS, Tiemeier H, Oostra BA, van Duijn CM, Janssens AC. Shared genetic factors in the co-occurrence of symptoms of depression and cardiovascular risk factors. J Affect Disord. 2010;122: 247-252.
27. Niranjan A, Corujo A, Ziegelstein RC, Nwulia E. Depression and heart disease in US adults. Gen Hosp Psychiatry. 2012;34:254-261.
28. Miyazaki S, Shah AJ, Haïssaguerre M. Early repolarization syndrome: a new electrical disorder associated with sudden cardiac death. Circ J. 2010;74:2039-2044.
29. Havránek S, Micek M, Paclt I, et al. QT dispersion estimated from 80 body surface potential map leads and from standard 12-leads ECG in psychiatric patients treated with dosulepin. Prague Med Rep. 2004;105: 53-63.
30. Nielsen J, Andersen MP, Graff C, et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand. 2010;121:385-388.
31. Raviña T, Suarez ML, Mendez-Castrillón J. Fluoxetine-induced QTU interval prolongation, T wave alternans and syncope. Int J Cardiol. 1998; 65:311-313.
32. Meert A, Vermeersch N, Beckers R, Hoste W, Brugada P, Hubloue I. Brugada-like ECG pattern induced by tricyclic antidepressants. Eur J Emerg Med. 2010;17:325-327.
33. Stirnimann G, Petitprez S, Abriel H, Schwick NG. Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine. Europace. 2010;12:282-283.
34. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev. 2005;24:205-214.
35. Lee MY, Kim SJ, Kim JS, Kang HS. Imipramine-induced cardiac depression is responsible for the increase in intracellular magnesium and the activation of ERK 1/2 in rats. J Cardiovasc Pharmacol Ther. 2010;15: 303-310.
36. Waring WS, Rhee JY, Bateman DN, Leggett GE, Jamie H. Impaired heart rate variability and altered cardiac sympathovagal balance after antidepressant overdose. Eur J Clin Pharmacol. 2008;64: 1037-1041.
37. Yang YC, Huang CS, Kuo CC. Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na+ channels. Anesthesiology. 2010;113:160-174.
38. Bradberry SM, Thanacoody HK, Watt BE, Thomas SH, Vale JA. Management of the cardiovascular complications of tricyclic antidepressant poisoning: role of sodium bicarbonate. Toxicol Rev. 2005;24: 195-204.
39. Linder AE, Diaz J, Ni W, Szasz T, Burnett R, Watts SW. Vascular reactivity, 5-HT uptake, and blood pressure in the serotonin transporter knockout rat. Am J Physiol Heart Circ Physiol. 2008;294:H1745-H1752.
40. Yilmaz Z, Ceschi A, Rauber-Lüthy C, et al. Escitalopram causes fewer seizures in human overdose than citalopram. Clin Toxicol. 2010;48: 207-212.
41. Waring WS, Gray JA, Graham A. Predictive factors for generalized seizures after deliberate citalopram overdose. Br J Clin Pharmacol. 2008; 66:861-865.
42. Pelat M, Verwaerde P, Tran MA, Berlan M, Senard JM, Montastruc JL. Changes in vascular alpha 1and alpha 2-adrenoceptor responsiveness by selegiline treatment. Fundam Clin Pharmacol. 2001;15:239-245.
43. Riederer P, Lachenmayer L, Laux G. Clinical applications of MAOinhibitors. Curr Med Chem. 2004;11:2033-2043.
44. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol. 1996;16:54S-59S.
45. Ferini-Strambi L, Manconi M, Castronovo V, Riva L, Bianchi A. Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia. J Psychopharmacol. 2004;18:417-422.
46. Chalon SA, Granier LA, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology. 2003;28:1685-1693.
47. Agelink MW, Ullrich H, Baumann B, Strum S, Majewski T. Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data. Psychopharmacology. 2002;163:151-156.
48. Paul M, Wichter T, Kies P, et al. Cardiac sympathetic dysfunction in genotyped patients with arrhythmogenic right ventricular cardiomyo-pathy and risk of recurrent ventricular tachyarrhythmias. J Nucl Med. 2011;52:1559-1565.
49. Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1999;291:280-284.
50. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol. 2007;64:192-197.
51. Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol. 2007;22:129-133.
52. Chan CY, Waring WS. Images in cardiovascular medicine. Tricyclic cardiotoxicity treated with sodium bicarbonate. Circulation. 2007;115: e63-e64.
53. Davison ET. Amitriptyline-induced torsade de pointes. Successful therapy with atrial pacing. J Electrocardiol. 1985;18:299-301.
54. Alter P, Tontsch D, Grimm W. Doxepin-induced torsade de pointes tachycardia. Ann Intern Med. 2001;135:384-385.
55. van Noord C, Straus S, Sturkenboom M et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol. 2009;29:9-15.
56. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother. 2002;3:479-498.
57. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004;45: 371-377.
58. Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med. 2000;18:227-229.
59. Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Keefover R. Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients. J Clin Psychiatry. 1982;43:8-15.
60. Studenik C, Lemmens-Gruber R, Heistracher P. Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers. Eur J Pharm Sci. 1999;7:113-118.
61. Jeon SH, Jaekal J, Lee SH, et al. Effects of nortriptyline on QT prolongation: a safety pharmacology study. Hum Exp Toxicol. 2011;30: 1649-1656.
62. Jo SH, Hong HK, Chong SH, Won KH, Jung SJ, Choe H. Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652. Eur J Pharmacol. 2008;592:19-25.
63. Aström-Lilja C, Odeberg JM, Ekman E, Hägg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2008;17:587-592.
64. Tarabar AF, Hoffman RS, Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol. 2008;4:101-105.
65. Lherm T, Lottin F, Larbi D, Bray M, Legall C, Caen D. Torsade de pointes after poisoning with fluoxetine alone. Presse Med. 2000;29: 306-307. French.
66. Mohammed R, Norton J, Geraci SA, Newman DB, Koch CA. Prolonged QTc interval due to escitalopram overdose. J Miss State Med Assoc. 2010;51:350-353.
67. Baranchuk A, Simpson CS, Methot M, Gibson K, Strum D. Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. Can J Cardiol. 2008;24: e38-e40.
68. Fayssoil A, Issi J, Guerbaa M, Raynaud JC, Heroguelle V. Torsade de pointes induced by citalopram and amiodarone. Ann Cardiol Angeiol. 2011;60:165-168. French.
69. Blaschke D, Parwani AS, Huemer M, et al. Torsade de pointes during combined treatment with risperidone and citalopram. Pharmacopsychiatry. 2007;40:294-295.
70. Digby G, Machaalany J, Malik P, et al. Multifactorial QT interval prolongation. Cardiol J. 2010;17:184-188.
71. Wenzel-Seifert K, Wittmann M, Haen E. Torsade de pointes episodes under treatment with selective serotonin reuptake inhibitors. Pharmacopsychiatry. 2010;43:279-281.
72. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int. 2011;108:687-693.
73. Deshmukh A, Ulveling K, Alla V, Abuissa H, Airey K. Prolonged QTc interval and torsades de pointes induced by citalopram. Tex Heart Inst J. 2012;39:68-70.
74. Kanjanauthai S, Kanluen T, Chareonthaitawee P. Citalopram induced torsade de pointes, a rare life threatening side effect. Int J Cardiol. 2008;131:e33-e34.
75. Tseng PT, Lee Y, Lin YE, Lin PY. Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review. Gen Hosp Psychiatry. 2012; 34:210. e13-e15.
76. Letsas K, Korantzopoulos P, Pappas L, Evangelou D, Efremidis M, Kardaras F. QT interval prolongation associated with venlafaxine administration. Int J Cardiol. 2006;109:116-117.
77. Fleishaker JC, Francom SF, Herman BD, Knuth DW, Azie NE. Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther. 2001;70:261-269.
78. O'Brien S, McKeon P, O'Regan M, O'Flaherty A, Patel R. Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline. J Clin Psychopharmacol. 1992;12: 104-109.
79. Waring WS, Wallace WA. Acute myocarditis after massive phenelzine overdose. Eur J Clin Pharmacol. 2007;63:1007-1009.
80. Downes MA, Whyte IM, Isbister GK. QTc abnormalities in deliberate self-poisoning with moclobemide. Intern Med J. 2005;35:388-391.
81. Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA adverse event reporting system (AERS). Pharmacoepidemiol Drug Saf. 2009;18: 512-518.
82. LoVecchio F, Riley B, Pizon A, Brown M. Outcomes after isolated mirtazapine (Remeron) supratherapeutic ingestions. J Emerg Med. 2008;34: 77-78.
83. Waring WS, Good AM, Bateman DN. Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. Clin Toxicol. 2007;45:45-50.
84. Krahn LE, Hanson CA, Pileggi TS, Rummans TA. Electroconvulsive therapy and cardiovascular complications in patients taking trazodone for insomnia. J Clin Psychiatry. 2001;62:108-110.
85. Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994;4:331-355.
86. Service JA, Waring WS. QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol. 2008; 46:71-73.
87. Waring WS. Delayed cardiotoxicity in chronic lithium poisoning: discrepancy between serum lithium concentrations and clinical status. Basic Clin Pharmacol Toxicol. 2007;100:353-355.
88. Waring WS, Laing WJ, Good AM, Bateman DN. Pattern of lithium exposure predicts poisoning severity: evaluation of referrals to a regional poisons unit. QJM. 2007;100:271-276.
89. Talati SN, Aslam AF, Vasavada B. Sinus node dysfunction in association with chronic lithium therapy: a case report and review of literature. Am J Ther. 2009;16:274-278.
90. Kayrak M, Duman C, Gul EE, Sonmez O, Kaya Z, Ari H. A bizarre electrocardiographic pattern due to chronic lithium therapy. Ann Noninvasive Electrocardiol. 2010;15:289-292.
91. Hsu CH, Liu PY, Chen JH, Yeh TL, Tsai HY, Lin LJ. Electrocardiographic abnormalities as predictors for over-range lithium levels. Cardiology. 2005;103:101-106.